Since many drugs that are effective against scrapie prions and extend survival in animal models fail to work in human prion diseases, it was crucial to validate the efficacy of EFV treatment in the human PrP–overexpressing transgenic tg650 model (42, 43). This evidence concerns the gene PRNP and prion disease.